Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2025Indian Journal of PharmacologyOpen Access

Synergistic activity of meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii

View Full Paper
Ask AI
Bookmark
Share

Authors

IAI. AmruthavarshiniDRDeepashree RajshekarRRRaghavendra Rao

Discussion

Loading...

Member takes

Overview

Observational analysis reveals 66.25% synergism in meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii, suggesting new treatment strategies.

Key Points

  • 66.25% of the tested combinations showed synergistic activity against carbapenem-resistant Acinetobacter baumannii, aiding treatment options.
  • Among the 80 CRAB isolates observed, all were resistant to meropenem, with 64 resistant to sulbactam, highlighting multidrug resistance.
  • The checkerboard assay method effectively determined the potential for drug synergism using combinations of meropenem and sulbactam.
  • This finding emphasizes the need for alternative therapeutic strategies in combating nosocomial infections caused by resistant bacterial strains.

Cite This Study

Amruthavarshini et al. (2025) studied this question.

synapsesocial.com/papers/68af706e7567bf4f94febe7ehttps://doi.org/10.4103/ijp.ijp_635_24
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-Resistant A. baumannii Clinical Isolates from Panama2025
  2. 2 activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant 2025
  3. 3Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method2025
  4. 4P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant <i>Acinetobacter baumannii</i> in India: an institutional experience2025
  5. 5From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?2025